纳米医学
纳米技术
药物输送
背景(考古学)
材料科学
溶致性
纳米材料
两亲性
纳米颗粒
溶致液晶
化学工程
胶束
液晶
脂质体
纳米载体
层状相
液晶
古生物学
光电子学
共聚物
复合材料
生物
聚合物
作者
Jiali Zhai,Celesta Fong,Nhiem Tran,Calum J. Drummond
出处
期刊:ACS Nano
[American Chemical Society]
日期:2019-05-13
卷期号:13 (6): 6178-6206
被引量:148
标识
DOI:10.1021/acsnano.8b07961
摘要
Nonlamellar lyotropic liquid crystalline (LLC) lipid nanomaterials have emerged as a promising class of advanced materials for the next generation of nanomedicine, comprising mainly of amphiphilic lipids and functional additives self-assembling into two- and three-dimensional, inverse hexagonal, and cubic nanostructures. In particular, the lyotropic liquid crystalline lipid nanoparticles (LCNPs) have received great interest as nanocarriers for a variety of hydrophobic and hydrophilic small molecule drugs, peptides, proteins, siRNAs, DNAs, and imaging agents. Within this space, there has been a tremendous amount of effort over the last two decades elucidating the self-assembly behavior and structure-function relationship of natural and synthetic lipid-based drug delivery vehicles in vitro, yet successful clinical translation remains sparse due to the lack of understanding of these materials in biological bodies. This review provides an overview of (1) the benefits and advantages of using LCNPs as drug delivery nanocarriers, (2) design principles for making LCNPs with desirable functionalities for drug delivery applications, (3) current understanding of the LLC material-biology interface illustrated by more than 50 in vivo, preclinical studies, and (4) current patenting and translation activities in a pharmaceutical context. Together with our perspectives and expert opinions, we anticipate that this review will guide future studies in developing LCNP-based drug delivery nanocarriers with the objective of translating them into a key player among nanoparticle platforms comprising the next generation of nanomedicine for disease therapy and diagnosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI